Effect of mexidol on the efficiency of intravenous thrombolytic therapy for ischemic stroke during the therapeutic window
This article is in "Library" section.
Author:
Knni K.S., Dyomin T.V., Adeeva L.B.
Interregional Clinical and Diagnostic Center, Kazan, Russia 12A, Karbyshev St., Kazan, Republic of Tatarstan 420101
Influence of mexidol and hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine on cerebral hemodynamics at hemorrhagic and ischemic damage of brain
Author:
I.N. KURDYUMOV1, T.S. GAN,SHINA1, D.V. MASLENNIKOV1, E.V. KURZA1, A.A. GORBUNOV1,2, A.I. TURILOVA1 and R.S. MIRZOYAN1
1 V.V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, ul. Baltiiskaya 8, Moscow. 125315 Russia
2 I.M. Sechenov First Moscow State Medical University (Sechenov University), ul. Trubetskaya 8, Moscow, 119881 Russia
Summary:
Comparative study of the effect of mexidol and hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine on the cerebral circulation of rats under conditions of hemorrhagic and ischemic brain lesions revealed significant differences in their cerebrovascular effects. Mexidol at a dose of 200 mg/kg i.v. better improves the local cerebral blood flow in modeling ischemia as compared to hemorrhagic brain damage. Hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine at a dose of 50 mg/kg better enhances the local blood supply to the cerebral cortex under conditions of hemorrhagic brain damage as compared to ischemic damage, since its cerebrovascular effect during cerebral ischemia occurs in a dose of 100 mg/kg. The mechanism of cerebrovascular anti-ischemic effect of 2-ethyl-6-methyl-3-hydroxypyridine hemisuccinate is mediated by GABAa receptors of the brain vessels, since bicuculline eliminates this effect.
Keywords: mexidol; hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine; bicuculline; cerebral circulation; hemorrhagic stroke model; global transient ischemia.
Influence of mexidol and hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine on cerebral hemodynamics at hemorrhagic and ischemic damage of brain
This article is in "Library" section.
Author:
I.N. KURDYUMOV1, T.S. GAN,SHINA1, D.V. MASLENNIKOV1, E.V. KURZA1, A.A. GORBUNOV1,2, A.I. TURILOVA1 and R.S. MIRZOYAN1
1 V.V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, ul. Baltiiskaya 8, Moscow. 125315 Russia
2 I.M. Sechenov First Moscow State Medical University (Sechenov University), ul. Trubetskaya 8, Moscow, 119881 Russia
The efficacy of mexidol for transient ischemic attacks in the vertebrobasilar system in elderly patients with chronic cerebral ischemia
This article is in "Library" section.
Author:
YU.V. ABRAMENKO
Tver State Medical University, Tver, Russia
Effect of mexidol on physical working efficiency and level of lactat in blood rats in conditions of light desynhronizes
This article is in "Library" section.
Author:
T.A. ZAMOSHCHINA, A.A. GOSTYUKHINA, K.V. ZAITSEV, M.V. SVETLIK, O.B. ZHUKOVA
Federal state budgetary institution «Siberian Federal science-clinical center of Federal medicobio-logical agency», Seversk, Russia; Siberian
State Medical University SSMU, Tomsk, Russia
Experience with mexidol in neurological practice
This article is in "Library" section.
Author:
O.A. GROMOVA, I.YU. TORSHIN, L.V. STAKHOVSKAYA, E.G. PEPELYAEV, V.A. SEMENOV, A.G. NAZARENKO
Federal Research Center «Informatics and Management», Institute of Pharmacoinformatics, RAS, Moscow, Russia; Research Institute of
Central Research Hospital of the Russian National Research Medical University. N.I. Pirogova, Moscow, Russia; FGBOU VO «Kemerovo
State Medical University» MH RF, Kemerovo, Russia; Federal State Autonomous Institution «National Medical Research Center for
Neurosurgery named after Academician N.N. Burdenko» of the Ministry of Health of the Russian Federation, Moscow, Russia
Mexidol® FORTE 250: the Expert Council members’ opinion of the therapeutic potential in the treatment of patients with cerebrovascular disease
In September, with the support of Vectorpharm LLC, an Expert Council of Neurologists and Clinical Pharmacologists was held, which was attended by leading Russian experts from Moscow, St. Petersburg, Novosibirsk, Volgograd, Kazan, Yaroslavl and other cities of Russia. The main topic was the discussion of medical application of a new form of domestic reference drug Mexidol® FORTE 250 in the dosage of 250 mg. The Council chairman and moderator was Professor A.I. Fedin.
The Council members emphasized the practical relevance and social significance of the new drug form - Mexidol® FORTE 250, the only active substance drug Ethylmethylhydroxypyridine succinate with a double dosage to be taken per os, which will allow to increase patients' adherence to therapy due to the convenience of taking medicines (3 tablets a day instead of 6).
At the end of the Expert Council meeting, the experts concluded that the use of Mexidol® and Mexidol® FORTE 250 was clinically grounded by the practical work of each doctor treating patients with cerebrovascular disorders, due to the proved high efficacy and safety of drugs. Particular importance is attached to therapy sequence, optimal dosages, treatment duration: thus, to achieve the maximum therapeutic effect, treatment should be started with intravenous injections of Mexidol® 10 ml (500 mg) for 10-15 days followed by tablet form of Mexidol® FORTE 250 mg 3 times a day for 4-6 weeks.
In conclusion, we can note that each report was extremely useful from the scientific and clinical points of view and caused the audience’s interest.
Arterial hypertension, cognitive disorders and dementia: a view of a cardiologist
Author:
O.D. OSTROUMOVA, M.S. CHERNIAEVA
Moscow State University of Medicine and Dentistry named after A.I. Evdakimov, Moscow, Russia; I.M. Sechenov First Moscow State
Medical University, Moscow, Russia; Central State Medical Academy of Department of Presidential Affairs, Moscow, Russia
Summary:
This article presents a review of Russian and foreign literature about the impact of arterial hypertension (AH) on the risk of cognitive impairment and dementia. Large studies have demonstrated the effect of blood pressure (BP) on the risk of vascular dementia and Alzheimer’s disease (AD) in elderly and oldest old people as well as a role of antihypertensive therapy. There is evidence of a negative effect of hypertension in middle age on cognitive functions in late-life. Observational studies as a whole have shown the positive effect of antihypertensive therapy on the prevention of cognitive function and dementia. However, there are a number of limitations that dictate the need for further research on this issue. The importance of the interdisciplinary approach to treatment of cognitive impairment by cardiologists and/or therapists, together with neurologists, as well as complex treatment regimens, including correction of risk factors and neuroprotective therapy, is highlighted.
Keywords: arterial hypertension, cognitive impairment, dementia, Alzheimer disease, antihypertensive therapy.
Arterial hypertension, cognitive disorders and dementia: a view of a cardiologist
This article is in "Library" section.
Author:
O.D. OSTROUMOVA, M.S. CHERNIAEVA
Moscow State University of Medicine and Dentistry named after A.I. Evdakimov, Moscow, Russia; I.M. Sechenov First Moscow State
Medical University, Moscow, Russia; Central State Medical Academy of Department of Presidential Affairs, Moscow, Russia
Role of antioxidants in treatment and prevention of patients with high risk of cardiovascular complications
This article is in "Library" section.
Author:
L.A. SHCHEPANKEVICH, M.M. TANASHYAN, YU.A. NIKOLAEV, V.YA. POLYAKOV, M.A. PERVUNINSKAYA, K.V. ANTONOVA
Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia; Neurology Research Center, Mosсow, Russia